Karyopharm Therapeutics Inc (KPTI) — Net Asset Quality Index
Karyopharm Therapeutics Inc (KPTI) has a Net Asset Quality Index of -270.2% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $108.42 Million minus total liabilities of $401.34 Million yields net assets of $-292.93 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are Karyopharm Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Karyopharm Therapeutics Inc Net Asset Quality Index Over Time (2011–2025)
This chart shows how Karyopharm Therapeutics Inc's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of December 2025, the index stands at -270.2%, representing net assets of $-292.93 Million against total assets of $108.42 Million USD. See Karyopharm Therapeutics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Karyopharm Therapeutics Inc (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Karyopharm Therapeutics Inc from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Karyopharm Therapeutics Inc (KPTI) market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -270.2% | $-292.93 Million | $108.42 Million | $401.34 Million | ▼ -157.1 pp |
| 2024 | -113.1% | $-186.02 Million | $164.42 Million | $350.44 Million | ▼ -56.5 pp |
| 2023 | -56.6% | $-136.21 Million | $240.44 Million | $376.64 Million | ▼ -52.0 pp |
| 2022 | -4.7% | $-16.66 Million | $358.17 Million | $374.83 Million | ▲ +21.4 pp |
| 2021 | -26.1% | $-79.67 Million | $305.31 Million | $384.98 Million | ▼ -42.2 pp |
| 2020 | 16.1% | $50.55 Million | $313.05 Million | $262.50 Million | ▼ -0.7 pp |
| 2019 | 16.9% | $49.77 Million | $294.96 Million | $245.19 Million | ▼ -36.8 pp |
| 2018 | 53.7% | $183.17 Million | $341.19 Million | $158.02 Million | ▼ -18.1 pp |
| 2017 | 71.8% | $129.46 Million | $180.29 Million | $50.83 Million | ▼ -18.1 pp |
| 2016 | 89.9% | $162.24 Million | $180.38 Million | $18.14 Million | ▼ -2.1 pp |
| 2015 | 92.1% | $198.37 Million | $215.44 Million | $17.08 Million | ▼ -1.8 pp |
| 2014 | 93.9% | $206.79 Million | $220.34 Million | $13.54 Million | ▼ -4.1 pp |
| 2013 | 97.9% | $154.93 Million | $158.23 Million | $3.29 Million | ▲ +2224.3 pp |
| 2012 | -2126.4% | $-27.88 Million | $1.31 Million | $29.19 Million | ▼ -1951.3 pp |
| 2011 | -175.1% | $-12.65 Million | $7.22 Million | $19.88 Million | — |